Rhinomed Limited (ASX:RNO) is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. The company is seeking to monetise applications of its technology portfolio in the Sport, Sleep, Wellbeing and Drug Delivery markets. For more information, go to www.rhinomed.global
Follow the Turbine on Twitter at @theturbinecom
Follow Mute Snoring on Twitter at @mutesnoring
Rhinomed (ASX:RNO) is pleased to announce it has seen strong progress in the commercialisation of its nasal technology platform during FY15Q3.
Rhinomed (ASX:RNO) presented the keynote address titled 'Changing the Way the World Breathes' at the 2015 Master Investor Show, held in London on 25th April 2015.
Rhinomed Ltd (ASX:RNO) develops, markets and partners it's internal nasal technology platform into multiple form factors - internal nasal devices.
Rhinomed (ASX:RNO) a Melbourne based sleep and respiratory technology company is pleased to advise that it will initiate a nation wide sleep trial this Saturday night.
Rhinomed (ASX:RNO) is pleased to advise CEO Michael Johnson has been invited to provide the keynote address on the Rising Stars Stage at the 2015 Master Investor Show (www.masterinvestor.co.uk) to be held in London on 25th April, 2015.
Rhinomed (ASX:RNO) is pleased to announce it has secured Australian wholesale pharmacy distribution with Symbion, part of the trans-Tasman EBOS Group, for its Mute(R) snoring and sleep quality technology.
Rhinomed Ltd (ASX:RNO) now has two products on the market. Having launched our first technology, Turbine(TM), into the Australian market for testing in January 2014, we have now released our new technology, Mute™ into the OTC snoring space.
The company has appointed Mr Christian Johnson as its Vice President, North America. Mr Johnson a seasoned sports industry executive was previously Vice President, Sales for GU Energy Labs, a high-growth, category leading, global sports nutrition brand.
The first six months of the financial year saw Rhinomed Ltd (ASX:RNO) consolidate its move into the sport market with its inaugural technology, Turbine, which was launched in January 2014. Our strategy is to use Australia as a test market before taking our branded technology to global markets.
Rhinomed Ltd (ASX:RNO) is pleased to announce the appointment of Justine Heath as its Chief Operating Officer/Chief Financial Officer effective from today.
